International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months

Trial Profile

International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Registrational; Therapeutic Use
  • Acronyms PLEO-CMT
  • Sponsors Pharnext
  • Most Recent Events

    • 29 Nov 2017 According to a Pharnext media release, final results are expected by the second half of 2018.
    • 29 Nov 2017 According to a Pharnext media release, intermediate futility analyses have been done and DSBM recomended to continue this trial according to the original plan without having to increase the trial size.
    • 26 Oct 2017 According to a Pharnext media release, data from this trial will be presented at the Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit for Charcot-Marie-Tooth (CMT) and Hereditary Neuropathy With Liability To Pressure Palsies (HNPP) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top